Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

rineterkib (LTT462)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Novartis

Drug class:

ERK2 inhibitor, ERK1 inhibitor

Related drugs:

BRAF G466A	Non Small Cell Lung Cancer	BRAF G466A	Non Small Cell Lung Cancer	ERAS-254 + LTT462 Sensitive: C3 – Early Trials ERAS-254 + LTT462 Sensitive : C3	ERAS-254 + LTT462 Sensitive: C3 – Early Trials ERAS-254 + LTT462 Sensitive : C3
BRAF V600E	Non Small Cell Lung Cancer	BRAF V600E	Non Small Cell Lung Cancer	ERAS-254 + LTT462 Sensitive: C3 – Early Trials ERAS-254 + LTT462 Sensitive : C3	ERAS-254 + LTT462 Sensitive: C3 – Early Trials ERAS-254 + LTT462 Sensitive : C3
BRAF mutation	Cholangiocarcinoma	BRAF mutation	Cholangiocarcinoma	LTT462 Sensitive: C4 – Case Studies LTT462 Sensitive : C4	LTT462 Sensitive: C4 – Case Studies LTT462 Sensitive : C4